Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Mortality Associated With Development of Squamous Cell Cancer in Patients With Inflammatory Bowel Disease Receiving Treatment With Thiopurines.

Khan N, Lee H, Trivedi C, Kavani H, Medvedeva E, Xie D, Lewis JD, Yang YX.

Clin Gastroenterol Hepatol. 2019 Mar 7. pii: S1542-3565(19)30254-X. doi: 10.1016/j.cgh.2019.03.005. [Epub ahead of print]

PMID:
30853615
2.

Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.

Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, Dray-Spira R.

JAMA. 2017 Nov 7;318(17):1679-1686. doi: 10.1001/jama.2017.16071.

3.

Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.

Khan N, Abbas AM, Lichtenstein GR, Loftus EV Jr, Bazzano LA.

Gastroenterology. 2013 Nov;145(5):1007-1015.e3. doi: 10.1053/j.gastro.2013.07.035. Epub 2013 Jul 25.

PMID:
23891975
4.

Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study.

Khan N, Patel D, Trivedi C, Shah Y, Lichtenstein G, Lewis J, Yang YX.

Clin Gastroenterol Hepatol. 2018 Dec;16(12):1919-1927.e3. doi: 10.1016/j.cgh.2017.12.052. Epub 2018 Jan 5.

PMID:
29309905
5.

Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.

Scott FI, Mamtani R, Brensinger CM, Haynes K, Chiesa-Fuxench ZC, Zhang J, Chen L, Xie F, Yun H, Osterman MT, Beukelman T, Margolis DJ, Curtis JR, Lewis JD.

JAMA Dermatol. 2016 Feb;152(2):164-72. doi: 10.1001/jamadermatol.2015.3029.

6.

Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease.

van Schaik FD, van Oijen MG, Smeets HM, van der Heijden GJ, Siersema PD, Oldenburg B.

Gut. 2012 Feb;61(2):235-40. doi: 10.1136/gut.2011.237412. Epub 2011 May 20.

PMID:
21602529
7.

Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort.

Abbas AM, Almukhtar RM, Loftus EV Jr, Lichtenstein GR, Khan N.

Am J Gastroenterol. 2014 Nov;109(11):1781-93. doi: 10.1038/ajg.2014.298. Epub 2014 Sep 23.

PMID:
25244964
8.

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.

Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P, Hugot JP, Lémann M, Nahon S, Sabaté JM, Tucat G, Beaugerie L; Cesame Study Group.

Gastroenterology. 2011 Nov;141(5):1621-28.e1-5. doi: 10.1053/j.gastro.2011.06.050. Epub 2011 Jun 25.

PMID:
21708105
9.

Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.

Beigel F, Steinborn A, Schnitzler F, Tillack C, Breiteneicher S, John JM, Van Steen K, Laubender RP, Göke B, Seiderer J, Brand S, Ochsenkühn T.

Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):735-44. doi: 10.1002/pds.3621. Epub 2014 Apr 30.

PMID:
24788825
10.

Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease.

Singh H, Nugent Z, Demers AA, Bernstein CN.

Gastroenterology. 2011 Nov;141(5):1612-20. doi: 10.1053/j.gastro.2011.07.039. Epub 2011 Jul 30.

PMID:
21806945
11.

Frequency of Herpes Zoster Vaccination Among Inflammatory Bowel Disease Patients.

Khan N, Trivedi C, Kavani H, Lewis J, Yang YX.

Inflamm Bowel Dis. 2019 Jan 10;25(2):345-351. doi: 10.1093/ibd/izy232.

PMID:
29982646
12.

Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.

Gómez-García M, Cabello-Tapia MJ, Sánchez-Capilla AD, De Teresa-Galván J, Redondo-Cerezo E.

World J Gastroenterol. 2013 Aug 14;19(30):4877-86. doi: 10.3748/wjg.v19.i30.4877.

13.

Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.

Hyams JS, Dubinsky MC, Baldassano RN, Colletti RB, Cucchiara S, Escher J, Faubion W, Fell J, Gold BD, Griffiths A, Koletzko S, Kugathasan S, Markowitz J, Ruemmele FM, Veereman G, Winter H, Masel N, Shin CR, Tang KL, Thayu M.

Gastroenterology. 2017 Jun;152(8):1901-1914.e3. doi: 10.1053/j.gastro.2017.02.004. Epub 2017 Feb 11.

PMID:
28193515
14.

The Severity of Herpes Zoster in Inflammatory Bowel Disease Patients Treated With Anti-TNF Agents.

Khan N, Trivedi C, Shah Y, Patel D, Lewis J, Yang YX.

Inflamm Bowel Dis. 2018 May 18;24(6):1274-1279. doi: 10.1093/ibd/izx115.

PMID:
29522099
15.

Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease.

Lopez A, Mounier M, Bouvier AM, Carrat F, Maynadié M, Beaugerie L, Peyrin-Biroulet L; CESAME Study Group.

Clin Gastroenterol Hepatol. 2014 Aug;12(8):1324-9. doi: 10.1016/j.cgh.2014.02.026. Epub 2014 Feb 26.

PMID:
24582568
16.

Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study.

Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R.

J Gastroenterol Hepatol. 2012 Feb;27(2):385-9. doi: 10.1111/j.1440-1746.2011.06865.x.

PMID:
21793904
17.

Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.

Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R.

Gastroenterology. 2018 Aug;155(2):337-346.e10. doi: 10.1053/j.gastro.2018.04.012. Epub 2018 Apr 12.

PMID:
29655835
18.

Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines.

Teruel C, López-San Román A, Bermejo F, Taxonera C, Pérez-Calle JL, Gisbert JP, Martín-Arranz M, Ponferrada A, Van Domselaar M, Algaba A, Estellés J, López-Serrano P, Linares PM, Muriel A.

Am J Gastroenterol. 2010 Sep;105(9):2003-8. doi: 10.1038/ajg.2010.138. Epub 2010 Aug 10.

PMID:
20700117
19.

Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.

Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, Loftus EV Jr, Peyrin-Biroulet L, Blonski WC, Van Domselaar M, Chaparro M, Sandilya S, Bewtra M, Beigel F, Biancone L, Lichtenstein GR.

Clin Gastroenterol Hepatol. 2015 May;13(5):847-58.e4; quiz e48-50. doi: 10.1016/j.cgh.2014.05.015. Epub 2014 May 28.

PMID:
24879926
20.

Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents.

Axelrad J, Bernheim O, Colombel JF, Malerba S, Ananthakrishnan A, Yajnik V, Hoffman G, Agrawal M, Lukin D, Desai A, McEachern E, Bosworth B, Scherl E, Reyes A, Zaidi H, Mudireddy P, DiCaprio D, Sultan K, Korelitz B, Wang E, Williams R, Chen L, Katz S, Itzkowitz S; New York Crohn's and Colitis Organization.

Clin Gastroenterol Hepatol. 2016 Jan;14(1):58-64. doi: 10.1016/j.cgh.2015.07.037. Epub 2015 Aug 3.

PMID:
26247164

Supplemental Content

Support Center